Evidence map›Paper›PMID 32713346›Full record

ArticleJournal of medical case reports2020

Transformation of a low-grade follicular lymphoma into a composite lymphoma combining a high-grade B-cell lymphoma and a lymphoblastic neoplasm expressing Terminal deoxynucleotidyl Transferase: a case report.

Antonin Bouroumeau, Eleonore Kaphan, Clémentine Legrand, Tatiana Raskovalova, Gautier Szymanski, Claire Vettier, Christine Lefebvre, Marie-Christine Jacob, Anne McLeer, Michel Peuchmaur and 2 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of medical case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Antonin BouroumeauDepartment of Pathology, CHU de Grenoble, Grenoble, France.
Eleonore KaphanDepartment of Hematology, CHU de Grenoble, Grenoble, France.
Clémentine LegrandLaboratory of Hematology and Oncohematology, CHU de Grenoble, Grenoble, France.
Tatiana RaskovalovaLaboratory of Hematology and Oncohematology, CHU de Grenoble, Grenoble, France.
Gautier SzymanskiLaboratory of Hematology and Oncohematology, CHU de Grenoble, Grenoble, France.
Claire VettierLaboratory of Hematology and Oncohematology, CHU de Grenoble, Grenoble, France.
Christine LefebvreLaboratory of Hematology and Oncohematology, CHU de Grenoble, Grenoble, France.
Marie-Christine JacobLaboratory of Hematology and Oncohematology, CHU de Grenoble, Grenoble, France.
Anne McLeerDepartment of Pathology, CHU de Grenoble, Grenoble, France.
Michel PeuchmaurDepartment of Pathology, CHU Robert Debre, Paris, France.
Rémy GressinDepartment of Hematology, CHU de Grenoble, Grenoble, France.
Hervé SarteletDepartment of Pathology, CHU de Grenoble, Grenoble, France. hsartelet@chu-grenoble.fr.ORCID http://orcid.org/0000-0002-3183-0125
Centre Hospitalier Universitaire de Grenoble · FRHôpital Robert-Debré · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6 is an aggressive mature B-cell neoplasm, whereas B-lymphoblastic lymphoma is immature cell proliferation, with a frequent positivity for terminal deoxynucleotidyl transferase. The transformation of a low-grade follicular lymphoma into a lymphoblastic neoplasm expressing terminal deoxynucleotidyl transferase is a very rare event. CASE PRESENTATION: A 55-year-old Caucasian man was followed for a grade 1-2 follicular lymphoma carrying a t(14;18) IGH/BCL2+ and was initially treated with R-CHOP. The follicular lymphoma presented two relapses. In the third relapse, the patient had multiple lymphadenopathy and ascites, which motivated a retroperitoneal biopsy and an ascitic tap. These samples were analyzed by histological, cytological, flow cytometric, cytogenetic, and molecular assessments. The patient died of a multiple organ dysfunction syndrome 2 weeks after his third relapse. The biopsy revealed a diffuse proliferation made up of two types of tumor cells: centroblasts (Bcl-6-positive) and immature cells (terminal deoxynucleotidyl transferase-positive). Flow cytometric analysis confirmed the immature phenotype, with an expression of terminal deoxynucleotidyl transferase, combined with a loss of membrane immunoglobulins. The cytogenetic analysis performed on the ascites revealed a clonal evolution characterized by a t(8;22)(q24;q11) MYC+ translocation not previously detected in follicular lymphoma. Fluorescence in situ hybridization confirmed the double rearrangement of the BCL2 and MYC genes. Polymerase chain reactions and sequencing were used to study the clonal relationship between follicular lymphoma and the secondary tumors. The IGVH gene rearrangement revealed a unique clonal rearrangement involving an IGVH4-59 subset in all three specimens.

conclusionThese findings suggest a clonal relationship between the two types of lymphoma cells. Furthermore, they support the transformation of an acute follicular lymphoma into a composite lymphoma combining a high-grade B-cell lymphoma and a lymphoblastic neoplasm expressing terminal deoxynucleotidyl transferase. This case report highlights the possible transformation of follicular lymphoma into a highly aggressive and immature proliferation.

Indexed as

Composite LymphomaLymphoma, B-CellLymphoma, FollicularDNA NucleotidylexotransferaseHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedTranslocation, GeneticDNA NucleotidylexotransferaseFollicular lymphomaHigh-grade B-cell lymphomaLymphoblastic neoplasmTdT

Identifiers

PMID32713346
PMCPMC7384216
OpenAlexW3045143276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.